frontier-banner
前沿速递
首页>前沿速递>

Nature Medicine | Efficacy and Mechanistic Insights of Neoadjuvant Botensilimab Combined with Balstilimab in pMMR and dMMR Colon Cancer

Nature Medicine | Efficacy and Mechanistic Insights of Neoadjuvant Botensilimab Combined with Balstilimab in pMMR and dMMR Colon Cancer
--

This study reveals a potential breakthrough for immune checkpoint inhibitors in mismatch repair-proficient (pMMR) colon cancer, offering new experimental design strategies for colon cancer immunotherapy, particularly regarding the combined application of PD-L1 and CTLA-4 targets.

 

Literature Overview

This article, titled "Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial," published in Nature Medicine, systematically explores the efficacy and safety of short-course neoadjuvant immune checkpoint inhibitors (ICIs) in resectable locally advanced colon cancer. The study specifically focuses on mismatch repair-proficient (pMMR) colon cancer, traditionally considered resistant to first-generation immunotherapy, evaluating the effects of the multifunctional Fc-enhanced anti-CTLA-4 monoclonal antibody botensilimab (BOT) alone or in combination with the anti-PD-1 monoclonal antibody balstilimab (BAL).

Background Knowledge

Colon cancer is a leading cause of cancer-related death globally. Despite curative-intent treatment, up to 35% of patients with locally advanced disease experience recurrence. Current treatment strategies show that mismatch repair-deficient (dMMR) colon cancer is highly sensitive to immune checkpoint inhibitors, whereas mismatch repair-proficient (pMMR) colon cancer is considered an immune "cold tumor" with poor response to traditional ICIs. This disease bottleneck limits the application of immunotherapy in a broader colon cancer population. Research on PD-1 and CTLA-4 targets in pMMR tumors currently faces bottlenecks, primarily due to a lack of T-cell infiltration and the presence of immunosuppressive mechanisms within the tumor microenvironment. The entry point of the UNICORN trial lies in leveraging the mechanism of Fc-enhanced CTLA-4 antibodies (BOT), which recruit and activate myeloid cells by activating Fcγ receptors (such as FCGR2A and FCGR3A), thereby enhancing antigen presentation and T-cell priming to overcome immune resistance in pMMR tumors. Additionally, the study integrates spatial transcriptomics, dynamic ctDNA monitoring, and gut microbiota analysis to deeply elucidate the biological characteristics of treatment response.

 

 

Research Methods and Experiments

This study employed a Phase II UNICORN trial design, an open-label, non-randomized, window-of-opportunity umbrella trial. The study enrolled 56 patients with resectable locally advanced pMMR or dMMR colon cancer, divided into four cohorts: pMMR BOT monotherapy, pMMR BOT+BAL combination, dMMR BOT monotherapy, and dMMR BOT+BAL combination. All patients received short-course preoperative treatment followed by surgical resection. The primary endpoint was the pathological major response (pMR) rate, defined as residual viable tumor ≤10%. Furthermore, the study conducted in-depth translational medical analyses, including single-cell spatial transcriptomics analysis (Visium HD) of paired tissue samples before and after treatment to assess cellular composition, spatial distribution, and gene expression dynamics within the tumor microenvironment; monitoring changes in immune cell subsets in peripheral blood mononuclear cells (PBMCs); analyzing fecal microbiota composition; and evaluating molecular response through longitudinal ctDNA detection.

Key Conclusions and Perspectives

  • In the pMMR BOT monotherapy group, the pMR rate was 0%, indicating limited efficacy of Fc-enhanced CTLA-4 antibody monotherapy in pMMR colon cancer.
  • In the pMMR BOT+BAL combination group, the pMR rate reached 36%, with 29% of patients achieving pathological complete response (pCR), demonstrating significant activity of combination therapy in pMMR tumors.
  • In the dMMR BOT monotherapy group, the pMR rate was 36%, while in the dMMR BOT+BAL combination group, the pMR rate reached 100%, with 93% of patients achieving pCR, confirming the superior efficacy of the combination regimen in dMMR tumors.
  • Spatial transcriptomics analysis showed that baseline characteristics of pMMR responders included high PD-L1 expression in the stroma and a significant reduction in regulatory T cell (Treg) features post-treatment; whereas dMMR responders exhibited high expression of FCGR2A and FCGR3A on intratumoral macrophages, suggesting the importance of FcγR-mediated mechanisms in dMMR.
  • Preoperative ctDNA clearance was highly correlated with pathological response and recurrence-free status; all patients with ctDNA clearance remained recurrence-free at the data cutoff, indicating that ctDNA is a powerful biomarker for predicting efficacy and prognosis.
  • In terms of safety, the treatment was generally well-tolerated, with the most common immune-related adverse events (irAEs) being flu-like syndrome and diarrhea; no treatment-related deaths occurred.

Research Significance and Prospects

From a research perspective, this study indicates that a dual blockade strategy targeting CTLA-4 and PD-1, particularly utilizing Fc-enhanced antibodies, can effectively overcome immune resistance in pMMR colon cancer, providing a new direction for drug development in early-stage colon cancer immunotherapy. For clinical monitoring, dynamic changes in ctDNA can serve as key indicators for assessing neoadjuvant treatment response and predicting recurrence, aiding in decisions regarding postoperative adjuvant therapy. Furthermore, the spatial characteristics of the tumor microenvironment revealed by the study (such as stromal PD-L1 expression and macrophage FCGR expression) provide potential biomarkers for future disease modeling and patient stratification, helping to screen patient populations more likely to benefit from immunotherapy.

 

 

Conclusion

The results of the UNICORN trial represent a major breakthrough in neoadjuvant immunotherapy for colon cancer, particularly in the pMMR subtype, long considered difficult to treat. By combining Fc-enhanced anti-CTLA-4 and anti-PD-1 antibodies, the study successfully induced significant pathological responses, achieving pathological complete response in some patients. This finding not only challenges the inherent perception of immune resistance in pMMR colon cancer but also provides new treatment strategies for clinical practice. The study emphasizes that integrating multi-dimensional biomarker analysis (such as spatial transcriptomics, ctDNA, and gut microbiota) enables a more precise understanding of treatment response mechanisms and optimizes patient selection. From a laboratory-to-clinic translational perspective, this study lays the foundation for building a more comprehensive colon cancer care system, with the potential to significantly improve patient prognosis and quality of life by shortening treatment cycles, increasing cure rates, and reducing unnecessary chemotherapy. Future research should further validate these findings and explore the long-term safety and efficacy of applying this combination regimen in larger populations.

 

Reference:
Filippo Ghelardi, Margherita Ambrosini, Alessandra Raimondi, Andrea Sottoriva, and Filippo Pietrantonio. Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial. Nature Medicine.
Protein Docking(HDOCK)
HDOCK uses a global search method based on Fast Fourier Transform (FFT) for sampling by a modified shape complementarity scoring method. During docking, one molecule (e.g. receptor) is fixed and the other molecule (e.g. ligand) is rotated uniformly in 3D Eulerian space. For each rotation of the ligand, the receptor and ligand are mapped onto a mesh and possible binding modes are exhaustively sampled in 3D translational space using the FFT method. The general case is rigid-body docking, although the flexibility problem can be handled indirectly by providing the residue information of the binding sites as constraints.